Molecular Partners

Molecular Partners, based in Zurich, Switzerland, is a radiopharmaceutical company. Molecular Partners develops DARPin (Designed Ankyrin Repeat Protein) therapeutics, including radiopharmaceuticals and immune cell engagers, mainly for cancer. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials, testing [212Pb]Pb-MP0712 and MP0533 with Obinutuzumab pretreatment in neuroendocrine tumours, non-small-cell lung cancer, pancreatic ductal adenocarcinoma, bladder & urothelial cancer and acute myeloid leukaemia. The largest, NCT05673057 (Study of MP0533 in Patients Acute Myeloid Leukaemia or Myelodysplastic Syndrome), plans to enrol 249 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.